Acute Pancreatitis
Has occurred in clinical trials. Discontinue use promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed.
Acute Gallbladder Disease
Has occurred in clinical trials. If lelithiasis is suspected, gallbladder studies and clinical follow-up are indicated.
Hypoglycemia
Concomitant use with an or insulin may secretagogue or insulinmay increase the risk of hypoglycemia, including severe hypoglycemia. Reducing the dose of insulin secretagogue or insulin may be necessary.
Inform all patients of the risk of hypoglycemia and educate them on the
signs and symptoms of hypoglycemia.
Acute Kidney Injury
Has occurred. Monitor renal function when initiating or escalating doses of WEGOVY in patients reporting severe adverse gastrointestinal reactions or in those with renal impairment reporting severe adverse gastrointestinal reactions.
Hypersensitivity
Anaphylactic reactions and angioedema have been reported post marketing. Discontinue WEGOVY if suspected and promptly seek medical advice.
Diabetic Retinopathy Complications in Patients with Type 2 Diabetes
Has been reported in trials with semiglutide. Patients with a history of diabetic retinopathy should be monitored.
Heart Rate Increase
Monitor heart rate at regular intervals.
Suicidal Behavior and Ideation
Monitor for depression or suicidal thoughts. Discontinue WEGOVY if symptoms develop.